Zymeworks (ZYME) and Its Competitors Head to Head Survey

Zymeworks (NASDAQ:ZYME) is one of 452 public companies in the “Pharmaceutical Preparations” industry, but how does it contrast to its competitors? We will compare Zymeworks to related companies based on the strength of its analyst recommendations, dividends, profitability, valuation, institutional ownership, risk and earnings.

Volatility and Risk

Zymeworks has a beta of 1.48, suggesting that its stock price is 48% more volatile than the S&P 500. Comparatively, Zymeworks’ competitors have a beta of 10.21, suggesting that their average stock price is 921% more volatile than the S&P 500.

Profitability

This table compares Zymeworks and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zymeworks	-59.96%	-21.59%	-16.52%
Zymeworks Competitors	-2,625.49%	-359.57%	-43.35%

Analyst Recommendations

This is a summary of recent ratings and target prices for Zymeworks and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zymeworks	1	1	0	3	3.00
Zymeworks Competitors	4806	9967	16004	371	2.38

As a group, “Pharmaceutical Preparations” companies have a potential upside of 127.25%. Given Zymeworks’ competitors higher possible upside, analysts clearly believe Zymeworks has less favorable growth aspects than its competitors.

Earnings and Valuation

This table compares Zymeworks and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Zymeworks	$134.48 million	-$122.69 million	-22.05
Zymeworks Competitors	$440.93 million	-$69.10 million	-10.03

Zymeworks’ competitors have higher revenue and earnings than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

92.9% of Zymeworks shares are owned by institutional investors. Comparatively, 39.4% of shares of all “Pharmaceutical Preparations” companies are owned by institutional investors. 1.9% of Zymeworks shares are owned by insiders. Comparatively, 13.8% of shares of all “Pharmaceutical Preparations” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Zymeworks competitors beat Zymeworks on 7 of the 13 factors compared.

Zymeworks Company Profile

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.